SCHEMBL3759007

SCHEMBL3759007

Cc1c(-c2ccccc2)[c]nc(N)c1C(=O)N1CCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KMT2A Q03164 3/20 0.46
HPGD P15428 5/20 0.43
ALDH1A1 P00352 3/20 0.43
GAA P10253 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALOX15 P16050 1/20 0.43
CASP1 P29466 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPK1 P28482 1/20 0.40
TSHR P16473 3/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
MDM2 Q00987 1/20 0.39
RECQL P46063 1/20 0.39
MEN1 O00255 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CNR1 P21554 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3761663 0.97 KMT2A (0.49) HTTSMN1; SMN2KMT2AHPGDALDH1A1
SCHEMBL4004236 0.80 SMN1; SMN2 (0.46) HTTSMN1; SMN2KMT2AHPGDALDH1A1
SCHEMBL4003843 0.80 KMT2A (0.46) HTTSMN1; SMN2KMT2AHPGDALDH1A1
SCHEMBL3760361 0.77 TP53 (0.48) HTTSMN1; SMN2KMT2AHPGDALDH1A1
SCHEMBL3765037 0.77 SIGMAR1 (0.47) HTTSMN1; SMN2KMT2AHPGDTSHR
SCHEMBL3759227 0.76 HTT (0.40) HTTSMN1; SMN2KMT2AHPGDMEN1
SCHEMBL3760358 0.74 TP53 (0.48) HTTSMN1; SMN2KMT2AHPGDALDH1A1
SCHEMBL3764989 0.74 SMN1; SMN2 (0.44) HTTSMN1; SMN2KMT2AHPGDALDH1A1
SCHEMBL3756655 0.74 HTT (0.48) HTTSMN1; SMN2KMT2AHPGDALDH1A1
SCHEMBL3756638 0.74 KMT2A (0.41) HTTSMN1; SMN2KMT2AHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA HTT 1234/4885SMN1; SMN2 1864/4885KMT2A 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.